![Doctor_reading_tablet_01](/var/esmo/storage/images/media/esmo-daily-reporter/images/aaa_generic-pictures-stock/doctors_reading/doctor_reading_tablet_01/19387061-1-eng-GB/doctor_reading_tablet_01_i770.jpg)
Cancer in old patients: geriatric assessment and management plays a crucial role to provide personalised care
First recommendations are released from the ESMO/SIOG Cancer in the Elderly Working Group
First recommendations are released from the ESMO/SIOG Cancer in the Elderly Working Group
Updated results from the KEYNOTE-564 trial confirm the role of pembrolizumab after surgery
In patients with metastatic castration-resistant prostate cancer, early genetic testing may help personalise treatments in the first-line as a study suggests
Survival benefits of the radioligand therapy needs to be confirmed in further studies
Cabozantinib plus atezolizumab may represent a novel option for patients progressing on first-line hormonal therapy
In US, the trend was more frequently seen at very low-volume and nonacademic centers than at high-volume and academic centers
A study reports evidence of antitumour activity by combining a GDF-15 neutralising antibody with PD-1 inhibition in cancers that are refractory/relapsed to immune checkpoint inhibitors
However, lack of OS benefit limits the clinical impact of the findings from the PSMAfore trial
Successful partnerships between industry and academia has had a positive impact on cancer drug discovery and development in prostate cancer
Positive outcomes in advanced or metastatic disease reported from EV-302/KEYNOTE-A39 and CheckMate 901 indicate an alternative to first-line chemotherapy for the first time
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.